GeNeuro: financial information and business update for the second quarter 2021
Geneva, Switzerland, July 23, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2021 second quarter cash position and issued a business update. https://geneuro.ch/data/news/GeNeuro-PR-Q2-2021-EN-VF.pdf
GeNeuro announces the publication in Multiple Sclerosis of results from CHANGE-MS and ANGEL-MS studies
Geneva, Switzerland, July 15, 2021 – 08:00am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical developing new treatments for neurodegenerative diseases, such as multiple sclerosis (MS), today announced publication in Multiple Sclerosis of the safety and efficacy results from its temelimab CHANGE-MS and ANGEL-MS clinical studies. https://geneuro.ch/data/news/GeNeuro-PR-MSJournal-publication-EN.pdf
GeNeuro: successful €6 million private placement
Geneva, Switzerland, July 13, 2021 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (“MS”), today announced the successful completion of a €6.0 million capital increase with cancellation of the preferential subscription […]
GeNeuro presents data supporting pathogenic role of an endogenous retroviral protein (HERV-W ENV) in post-COVID neuropsychiatric syndrome Enters collaboration with the FondaMental Foundation to speed development of diagnostic and therapeutic…
Paris, France and Geneva, Switzerland, July 5, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), presented new data showing that the neuropsychiatric symptomatology seen in “post-COVID” patients may be due to activation of HERV-W ENV expression in […]
GeNeuro and CIRI Renew Collaboration Agreement and Expand Focus to Post-COVID Syndromes
Geneva, Switzerland, June 24, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), and the CIRI (International Center for Infectiology Research), in Lyon, France, a world-class research institute against infectious diseases, announced today the signing of an extension […]
GeNeuro Announces Approval of all Resolutions Proposed at 2021 Annual General Meeting
Geneva, Switzerland, June 1, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2021. These included among others: https://geneuro.ch/data/news/GeNeuro-AGM-01062021-EN-1-.pdf
Availability of documents and information for the annual shareholders’ meeting of May 27, 2021
Geneva, Switzerland, May 6, 2021 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurologic and autoimmune diseases, including multiple sclerosis, informs its shareholders that the Annual General Meeting will be held on Thursday May 27, 2021 at 9.30am at its head office, 3, chemin du Pré-Fleuri, 1228 […]
Researchers Detect HERV-W ENV in COVID-19 Patients and Link Expression to Disease Severity
Data published in the Lancet’s EBioMedicine shows that the pathogenic envelope protein of the human endogenous retrovirus W (HERV-W ENV) is found on lymphocytes of hospitalized patients with COVID-19, and that its level of expression is associated with disease severity. https://geneuro.ch/data/news/GeNeuro-HERV-and-Covid-ENG-April-15-2021.pdf
GeNeuro : financial information for the first quarter 2021
Geneva, Switzerland, April 9, 2021 – 6.00pm CEST Strong financial situation and visibility: https://geneuro.ch/data/news/GeNeuro-PR-Q1-2021-EN.pdf
GeNeuro Reports 2020 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 6, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a clinical-stage biopharmaceutical company leveraging the biology of human endogenous retroviruses (HERVs) to develop new treatments to stop the progression of neurodegenerative and autoimmune diseases, reported today its full-year results for the year ended December 31, 2020 and provided a corporate […]